KMT2A and leukemia: Disruption of SGF29 (via genetic suppression or the Tudor domain inhibition) suppresses leukemia progression in vitro and in vivo, providing critical rationales toward an effective therapy against hematopoietic cancers, including the more malignant subtypes such as the leukemias with MLL gene translocations.